Company profile for Algernon Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientis...
Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
Suite 915 – 700 West Pender Street Vancouver, BC
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/29/3196492/0/en/Algernon-Closes-Second-Tranche-of-Private-Placement-Financing.html

GLOBENEWSWIRE
28 Nov 2025

https://www.globenewswire.com/news-release/2025/11/15/3188679/0/en/Algernon-Closes-First-Tranche-of-its-Recently-Announced-Private-Placement-Financing.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3166926/0/en/Algernon-Pharmaceuticals-Completes-Name-Change-to-Algernon-Health.html

GLOBENEWSWIRE
15 Oct 2025

https://www.prnewswire.com/news-releases/catalyst-medtech-launches-connect-program-to-expand-access-to-advanced-imaging-announces-initial-partnership-with-algernon-pharmaceuticals-302577032.html

PR NEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/09/25/3156149/0/en/Algernon-Announces-CAD-4-Million-Non-Dilutive-Financing-to-Open-Four-Brain-Specific-PET-Scan-Clinics-in-the-U-S-for-Early-Stage-Alzheimer-s-Detection.html

GLOBENEWSWIRE
25 Sep 2025

https://www.globenewswire.com/news-release/2025/09/19/3153410/0/en/Algernon-Announces-Preferred-Share-Class-Approved-at-Annual-and-Special-Meeting.html

GLOBENEWSWIRE
19 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty